Dr. Torok is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Drive
Division Of Gastroenterology
Stanford, CA 94305Phone+1 650-498-6080- Is this information wrong?
Summary
- Our primary research interest is in liver fibrosis and matrix remodeling, and their role in the development of hepatocellular carcinoma.
Clinically, metabolic dysfunction associated steatohepatitis (MASH) is becoming the leading cause of chronic liver disease and liver cancer, and we are interested in deciphering how dynamic changes in the liver matrix accelerate this process in certain conditions such as type 2 diabetes. Of particular interest are studies on collagen architecture and connectivity and how these are implicated in mechanosensing. We are also focusing on aging-related pathways and wound healing processes. We are exploring the age-related modulation of hepatocyte stress signals, metabolic changes, and how these intersect with innate immune responses and matrix modulation in the liver. Based on these studies we have identified targets for novel small molecule inhibitors to treat fibrosis, and are performing investigator-initiated clinical trials.
As MASH is becoming the most common liver disease in the US and worldwide our ultimate goal is to target high-risk populations, and to develop novel therapeutic approaches that reverse fibrosis and improve patient outcomes.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1999 - 2003
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1996 - 1999
- Semmelweis UniversityClass of 1988
Certifications & Licensure
- CA State Medical License 2003 - 2025
- MN State Medical License 1999 - 2017
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Clinical Trials
- The Role of Leptin Receptors in NASH Start of enrollment: 2006 Jan 01
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Start of enrollment: 2021 Jul 30
- Novel MRE Technique to Assess a Risk Factor for Liver Cancer Start of enrollment: 2022 Jan 27
Roles: Principal Investigator, Contact, Sponsor-Investigator
Publications & Presentations
PubMed
- 26 citationsDigoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis.Xinshou Ouyang, Sheng-Na Han, Ji-Yuan Zhang, Evangelos Dioletis, Balazs Tamas Nemeth
Cell Metabolism. 2018-02-06 - 7 citationsPatterns and co-occurrence of risk factors for hepatocellular carcinoma in four Asian American communities: a cross-sectional study.Susan L. Stewart, Julie H.T. Dang, Natalie J. Török, Moon S. Chen
BMJ Open. 2019-06-28 - 49 citationsNADPH Oxidases in Chronic Liver Diseases.Joy X. Jiang, Natalie J. Török
Advances in Hepatology. 2014-11-30
Press Mentions
- New Screening Guidelines for Diabetes and Liver CancerFebruary 5th, 2024
- Liver Cancer and t2 Diabetes: Here's Why They Are RelatedFebruary 7th, 2024
Hospital Affiliations
- VA Palo Alto Heath CarePalo Alto, California
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: